StocksFin Logo
Impel Pharmaceuticals Inc. country of incorporation
|
|
Mr. Adrian Adams
|
129 employees
NASDAQ | Healthcare | Biotechnology
NASDAQ | Healthcare | Medical Devices
Q322 reported Nov 14, 2022 Reporting Period
$3.08M 3386713.2% vs. Q321 Revenues Q322
51.07% 129.2% vs. Q321 Gross Profit Margin
-1000% ! 0% vs. Q321 Net Profit Margin
-47.05M ! -173.1% vs. Q321 Free Cash Flow Q322
$-1.31 ! -50284.6% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
Q123 reported Dec 31, 2022 Reporting Period
$40.82M 38.2% vs. Q122 Revenues Q123
75.32% 1.7% vs. Q122 Gross Profit Margin
0.8% 111% vs. Q122 Net Profit Margin
3.53M -34.5% vs. Q122 Free Cash Flow Q123
$0.01 116.7% vs. Q122 EPS Q123
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
Ratios
As of
Sep 30, 2022
Dec 31, 2022
Quick Ratio
4.3
0.56
Current Ratio
4.97
1.05
Cash Ratio
3.99
0.1
Price to Book
-5.18
2.08
Price to Sales
37.46
4.11
Price to Earnings
-0.93
129